Founded in 2010, Personal Genome Diagnostics (PGDx) specializes in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. They have developed novel technologies for non-invasive "liquid biopsy" approaches in cancer, empowering oncology researchers, drug developers, clinicians, and patients to address cancer-related genetic changes. With a commitment to developing a portfolio of regulated tissue-based and liquid biopsy genomic products, PGDx offers expertise in advanced cancer genome analysis, ranging from sample preparation and sequencing to data interpretation and analysis. Founders Luis Diaz and Victor Velculescu are internationally recognized leaders in cancer genomics, known for their application of innovative genomic technologies in drug development and clinical practice.